InMed Pharmaceuticals Inc.

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors. Their pipeline includes programs for the treatment of Alzheimer's disease, ocular, and dermatological indications.

Products & Services

INM-901:A drug candidate for Alzheimer's disease demonstrating neuroprotective effects, neurite extension for brain cell communication, and reduction in neuroinflammation in preclinical studies.

INM-089:A treatment for age-related macular degeneration, with an intravitreal formulation under development.

INM-755:A cannabinol (CBN) topical cream that has completed a Phase 2 clinical trial for epidermolysis bullosa.

INM-088:A drug candidate for the treatment of glaucoma.

Novel Cannabinoid Analogs:Patentable analogs with modifications to target specific pharmacological properties for various diseases.

BayMedica - Rare Cannabinoid Ingredients:A portfolio of premium bioidentical rare cannabinoids (CBC, d9-THCV, CBDV, CBTC) manufactured with high purity for health and wellness products.

IntegraSyn™ Cannabinoid Manufacturing:A proprietary manufacturing process for cannabinoids.

INM-901 (Alzheimer’s disease)

INM-089 (dry age-related macular degeneration)

INM-755 (epidermolysis bullosa)

Specialties

Small molecule therapeutics CB1/CB2 receptor targeting Alzheimer's disease treatment Ocular disease treatment Dermatological treatment Cannabinoid manufacturing Rare cannabinoid ingredients small molecule therapeutics neuroinflammation ocular disease dermatological disease

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Preferred Investment Options Amendment T: - FT: Preferred Investment Options Amendment	A: 1843771 MR: - FA: Potential up to $1,843,771 based on amended options for 2,304,714 shares at $0.80 each FAN: 1843771	D: 2026-04-27 FD: 2026-04-27	2 investors
2	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2025-06-27 FD: 2025-06-27	-
3	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: approximately $5 million FAN: 5000000	D: 2025-06-25 FD: 2025-06-25	1 investors

Preferred Investment Options Amendment Latest

2026-04-27

$1.8M

2 investors (Pro only)

Private Placement 2025-06-27

$5.0M

Private Placement 2025-06-25

$5.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Eric Adams

Chief Executive Officer & President

M

Michael Woudenberg

Chief Operating Officer

N

Netta Jagpal

Chief Financial Officer

E

Eric Hsu

Senior Vice President, Pre-Clinical Research & Development

C

Colin Clancy

Vice President, Investor Relations & Corporate Communications

C

Charles Marlowe

VP, Chemistry

View 12 more team members with Pro

Unlock Full Team Directory

Recent News